These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 17331716)
1. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors. Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179 [TBL] [Abstract][Full Text] [Related]
3. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors. Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541 [TBL] [Abstract][Full Text] [Related]
4. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. Castilho MS; Guido RV; Andricopulo AD Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors. Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400 [TBL] [Abstract][Full Text] [Related]
6. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Kee P; Caiazza D; Rye KA; Barrett PH; Morehouse LA; Barter PJ Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):884-90. PubMed ID: 16373610 [TBL] [Abstract][Full Text] [Related]
7. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors. Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028 [TBL] [Abstract][Full Text] [Related]
9. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Schaefer EJ; Asztalos BF Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. Reinhard EJ; Wang JL; Durley RC; Fobian YM; Grapperhaus ML; Hickory BS; Massa MA; Norton MB; Promo MA; Tollefson MB; Vernier WF; Connolly DT; Witherbee BJ; Melton MA; Regina KJ; Smith ME; Sikorski JA J Med Chem; 2003 May; 46(11):2152-68. PubMed ID: 12747787 [TBL] [Abstract][Full Text] [Related]
11. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Masson D Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Fernandez MC; Escribano A; Mateo AI; Parthasarathy S; Martin de la Nava EM; Wang X; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel A; Sweetana SA; Cannady EA; Stephenson G; Frank S; Mantlo NB Bioorg Med Chem Lett; 2012 May; 22(9):3056-62. PubMed ID: 22497761 [TBL] [Abstract][Full Text] [Related]
13. The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer. Dullaart RP; Borggreve SE; Hillege HL; Dallinga-Thie GM Scand J Clin Lab Invest; 2008; 68(2):99-105. PubMed ID: 17852818 [TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
16. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice. Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047 [TBL] [Abstract][Full Text] [Related]
17. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257 [TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein: a fall from grace? van Leuven SI; Stroes ES; Kastelein JJ Ann Med; 2008; 40(8):584-93. PubMed ID: 18608128 [TBL] [Abstract][Full Text] [Related]